The U.K. removes Keytruda from Cancer Drug Fund in bladder cancer indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

England’s National Institute for Health and Care Excellence has rejected Keytruda (pembrolizumab) in patients who receive locally advanced or metastatic urothelial carcinoma who have had platinum-containing chemotherapy.

Merck sponsors Keytruda.

The drug has since been removed from the Cancer Drug Fund, where it was available previously.

The National Institute for Health and Care Excellence said it couldn’t recommend the drug because of cost-effectiveness.

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more

Login